Holen Sie sich die Stockscreener-App
76.29
2.19%
-1.71
Handel nachbörslich:
75.89
-0.40
-0.52%
Schlusskurs vom Vortag:
$78.00
Offen:
$78.8
24-Stunden-Volumen:
2.37M
Relative Volume:
1.42
Marktkapitalisierung:
$13.65B
Einnahmen:
$342.96M
Nettoeinkommen (Verlust:
$-864.29M
KGV:
-13.75
EPS:
-5.55
Netto-Cashflow:
$-636.03M
1W Leistung:
-1.99%
1M Leistung:
+10.77%
6M Leistung:
+4.64%
1J Leistung:
+163.34%
1-Tages-Spanne:
$75.57
$80.63
1-Wochen-Bereich:
$75.57
$80.63
52-Wochen-Spanne:
$21.92
$80.63
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
76.29 | 13.65B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Moody Aldrich Partners LLC Purchases New Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
BEFORE THE BELL-Insmed shares down after Iplex move - Reuters
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Park Avenue Securities LLC - Defense World
Truist maintains Buy on Insmed stock, price target steady at $105 - MSN
Brokers Set Expectations for Insmed FY2025 Earnings - Defense World
FY2026 EPS Estimates for Insmed Decreased by Leerink Partnrs - Defense World
Leerink Partnrs Has Weak Estimate for Insmed FY2026 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on Insmed FY2025 Earnings - MarketBeat
Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight - GlobeNewswire Inc.
The five-year returns have been solid for Insmed (NASDAQ:INSM) shareholders despite underlying losses increasing - Yahoo Finance
Insmed CEO William Lewis sells shares worth $2.71 million - MSN
Insmed Incorporated (NASDAQ:INSM) Short Interest Up 18.7% in December - MarketBeat
Is Insmed (NASDAQ:INSM) Using Debt Sensibly? - Simply Wall St
Insmed chief medical officer sells $95,108 in stock - MSN
Is Insmed Incorporated (INSM) One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Yahoo Finance
Insmed (FRA:IM8N) Shares Outstanding (EOP) : 178.8 Mil (As of Sep. 2024) - GuruFocus.com
Insmed's chief people strategy officer sells $59,923 in stock - MSN
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert - MSN
Insmed Incorporated (NASDAQ:INSM) Insider Sells $95,108.48 in Stock - MarketBeat
Insider Selling: Insmed Incorporated (NASDAQ:INSM) COO Sells 1,457 Shares of Stock - MarketBeat
Insmed COO Roger Adsett sells $100,125 in stock - MSN
Hennion & Walsh Asset Management Inc. Sells 43,522 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed chief medical officer sells $95,108 in stock By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Has $36.26 Million Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insider Sell: Martina Flammer Sells 1,384 Shares of Insmed Inc ( - GuruFocus.com
Insider Sell: Schaeffer Orlov S Nicole Sells Shares of Insmed In - GuruFocus.com
Insmed's chief people strategy officer sells $59,923 in stock By Investing.com - Investing.com Australia
Insmed COO Roger Adsett sells $100,125 in stock By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells shares worth $2.71 million By Investing.com - Investing.com Canada
Why INSM Stock Is Advancing Today - MSN
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance - Yahoo Finance
Capital CS Group LLC Buys New Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (NASDAQ:INSM) Stock Price Up 6%Should You Buy? - MarketBeat
How Is The Market Feeling About Insmed? - Benzinga
Insmed issues preliminary revenue results, guidance for Arikayce - MSN
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):